Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization

• প্রধান লেখক: Hongjie Mu (লেখক), Yiyun Wang (লেখক), Yongchao Chu (লেখক), Ying Jiang (লেখক), Hongchen Hua (লেখক), Liuxiang Chu (লেখক), Kaili Wang (লেখক), Aiping Wang (লেখক), Wanhui Liu (লেখক), Youxin Li (লেখক), Fenghua Fu (লেখক), Kaoxiang Sun (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Bevacizumab is an anti-vascular endothelial growth factor drug that can be used to treat choroidal neovascularization (CNV). Bevacizumab-loaded multivesicular liposomes (Bev-MVLs) have been designed and developed to increase the intravitreal retention time of bevacizumab and reduce the number of inj...